Clinical Trial Update: An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating fedratinib versus best available therapy in high- or intermediate-risk myelofibrosis subtypes after ruxolitinib failure has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• fedratinib (fedratinib)

Snippet

Sponsor: Celgene | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera | Phase 3 | Status: COMPLETED | Results posted: 2024-01-30